Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries - - Both Applications Will Be Assessed in Parallel ...

The Rwanda Biomedical Center (RBC) said last week that the government plans to introduce lenacapavir, a long-acting ...

Kenya has taken a major step towards expanding HIV prevention options after the Ministry of Health formally recommended the ...

At least 1.4 million Kenyans are living with HIV, with approximately 21,009 people estimated to have died from AIDS-related ...

Kenya is now among the first African countries to recommend Lenacapavir for registration, a move the Ministry said aligns ...

Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...

A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...

By Puyaan Singh Jan 12 (Reuters) - Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial ...

Seeking to prevent the spread of HIV, Unitaid is providing $31 million to South Africa and Zambia in hopes of widening access ...